Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 337

1.

Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases.

Bricks LF, Berezin E.

J Pediatr (Rio J). 2006 Jul;82(3 Suppl):S67-74. Epub 2006 May 19. Review.

2.

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B.

Pediatr Infect Dis J. 2004 Jun;23(6):485-9.

PMID:
15194827
3.

[Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine].

de Arístegui Fernández J, Corretger Rauet JM, García Martín F, Hernández-Sampelayo T, Moraga Llop FA, Rodrigo Gonzalo De Liria C, Ruiz Contreras J; Comité Asesor deVacunas de la Asociación Española de Pediatría..

An Esp Pediatr. 2002 Jan;56(1):79-90. Review. Spanish.

PMID:
11792258
4.

A conjugate vaccine for the prevention of pediatric pneumococcal disease.

Murray D, Jackson C.

Mil Med. 2002 Aug;167(8):671-7. Review.

PMID:
12188240
5.

Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine.

Aristegui J, Bernaola E, Pocheville I, García C, Arranz L, Durán G, Pérez L, Bastida M, Canduela C, Herranz Aguirre M, Garrote E, Fletcher MA, Pérez C.

Eur J Clin Microbiol Infect Dis. 2007 May;26(5):303-10.

PMID:
17457623
6.

Pneumococcal conjugate vaccine for young children.

Selman S, Hayes D, Perin LA, Hayes WS.

Manag Care. 2000 Sep;9(9):49-52, 54, 56-7 passim. Review.

7.

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, Griffin MR.

Pediatrics. 2006 Sep;118(3):865-73.

PMID:
16950975
8.

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.

Eur J Health Econ. 2008 Feb;9(1):7-15. Epub 2007 Mar 2.

PMID:
17333089
9.

The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.

Toltzis P, Jacobs MR.

Infect Dis Clin North Am. 2005 Sep;19(3):629-45. Review.

PMID:
16102653
10.

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.

Hennessy TW, Singleton RJ, Bulkow LR, Bruden DL, Hurlburt DA, Parks D, Moore M, Parkinson AJ, Schuchat A, Butler JC.

Vaccine. 2005 Dec 1;23(48-49):5464-73. Epub 2005 Sep 12.

PMID:
16188350
12.

A new conjugate vaccine against pneumococcal disease.

Wilson-Adkins M, Adkins C.

Nurse Pract. 2001 May;26(5):52, 55-6, 59-62. Review.

PMID:
11383494
13.

Empiric first-line antibiotic treatment of acute otitis in the era of the heptavalent pneumococcal conjugate vaccine.

Garbutt J, Rosenbloom I, Wu J, Storch GA.

Pediatrics. 2006 Jun;117(6):e1087-94.

PMID:
16740811
14.

Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.

Albrich WC, Baughman W, Schmotzer B, Farley MM.

Clin Infect Dis. 2007 Jun 15;44(12):1569-76. Epub 2007 May 8.

PMID:
17516400
15.

Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).

Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J.

Vaccine. 2007 Mar 22;25(13):2420-7. Epub 2006 Sep 18.

PMID:
17049677
16.

[Pediatrics. Conjugate anti-pneumoccoccal vaccine: what are the results four years after introduction?].

Myers C, Gervaix A.

Rev Med Suisse. 2005 Jan 12;1(2):142, 144, 146-7. French.

PMID:
15773216
17.

[Incidence of invasive pneumococcal infection in children aged less than two years. The heptavalent pneumococcal conjugate vaccine. Situation in Spain].

Blanco Quirós A, Giménez Sánchez F, Asensi Botet F, Bernaola Iturbe E, Martín Fde J, García Pérez J, Garcés Sánchez M, Gómez Campderá JA, Picazo JJ, Pineda Solas V; Comité Asesor de Vacunas de la Asociación Española de Pediatría..

An Esp Pediatr. 2002 Oct;57(4):287-9. Spanish. No abstract available. Erratum in: An Esp Pediatr. 2002 Nov;57(5):393. Jimenez Sanchez, F [corrected to Giménez Sánchez, F].

PMID:
12392660
18.

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8.

19.

Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine.

Whitney CG, Klugman KP.

Semin Pediatr Infect Dis. 2004 Apr;15(2):86-93. Review.

PMID:
15185191
20.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135

Supplemental Content

Support Center